Press releases

Contera Pharma (“Contera”), subsidiary of Bukwang Pharmaceutical (“Bukwang”), announced 51 billion KRW Series B financing from Korean institutional investors. The size of the current round has increased more than 17-fold compared to series A financing in 2019. Contera, is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders. The […]

Contera Pharma, a subsidiary of Bukwang, announced that it elected Dr. Thomas Sager as CEO while further expanding the executive management team to include representatives for Business Development and R&D Chief Executive Officer; Thomas Sager, PhD. Chief Business Officer; Anders Brandt Elvang, PhD. Chief Science Officer; Kenneth Vielsted Christensen, PhD. Thomas Sager, received his PhD […]